Monthly Headaches and Severity in Patients on Galcanezumab or Traditional Preventive Migraine Medication: A 24-Month Claims and Electronic Health Records Study
Abstract Introduction Migraine, affecting millions globally, imposes a significant burden on patients and healthcare systems. Calcitonin gene-related peptide monoclonal antibodies are recommended as first-line preventive treatments by international guidelines, yet real-world prospective studies comp...
Saved in:
| Main Authors: | Oralee J. Varnado, Michelle Vu, Gilwan Kim, Margaret Hoyt, Erin Buysman, Abhinav Nayyar, Shikha Anand, Lars Viktrup |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-04-01
|
| Series: | Neurology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40120-025-00742-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Migren Profilaksisinde Etkili Bir Ajan; Galcanezumab: Tek Merkez Deneyimleri
by: Sena Boncuk Ulaş, et al.
Published: (2024-09-01) -
Do Headache Pain Intensity and Headache Days Influence Psychiatric Comorbidities in Patients with Migraine?
by: Vivek Dave, et al.
Published: (2025-06-01) -
Medication underuse in real-life practice: the impact of galcanezumab towards achieving very low frequency episodic migraine in a southeast Asian middle-income nation
by: Wanakorn Rattanawong, et al.
Published: (2025-01-01) -
Shift from chronic to episodic migraine frequency in a long-term phase 3 study of galcanezumab
by: Hans-Christoph Diener, et al.
Published: (2025-02-01) -
Cerebral Artery Vasoconstriction After Galcanezumab Loading Dose for Migraine Prevention: A Case Report
by: Thanin Asawavichienjinda, et al.
Published: (2024-10-01)